Quantum Capital Management Decreased Its Stake in Biomarin Pharmaceutical INC (BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Corporate LogoDuring 2018 Q2 the big money sentiment increased to 1.21. That’s change of 0.25, from 2018Q1’s 0.96. 30 investors sold all, 118 reduced holdings as BMRN ratio improved. 122 increased holdings while 57 funds bought holdings. Funds hold 177.65 million shares thus 1.83% more from 2018Q1’s 174.46 million shares. State Of Alaska Department Of Revenue owns 21,290 shs. Sun Life Fin invested in 0.01% or 500 shs. Balyasny Asset Lc holds 416,770 shs or 0.18% of its capital. Utah Retirement Sys holds 0.06% or 32,581 shs in its capital. Clarivest Asset Management Lc holds 3 shs or 0% of its capital. 241,695 were accumulated by Torray Ltd Liability Corp. Essex Llc invested in 12,433 shs or 0.15% of the stock. Bailard accumulated 5,000 shs. 1,000 were reported by Gemmer Asset Management Ltd Liability Co. Hsbc Hldg Public Limited Company reported 20,902 shs. Cqs Cayman Lp owns 176,500 shs. Prelude Cap Mngmt Limited Liability Company reported 4,379 shs stake. Parametric Portfolio Associate Lc owns 243,506 shs. Ithaka Grp Lc holds 0.86% or 58,626 shs. Moreover, Gsa Capital Ltd Liability Partnership has 0.02% invested in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

BMRN had 19 selling transactions and 0 insider purchases since May 14, 2018. This’s net activity of $14.60 million. Another trade for 2,021 shs valued at $190,985 was sold by Mueller Brian. On Friday, September 14 a trade for 2,216 shs valued at $220,386 was made by Davis George Eric. HERON ELAINE J had sold 1,000 shs worth $96,935 on Wednesday, September 5. On Wednesday, June 27 $201,068 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was sold by LAWLIS V BRYAN. $687,954 worth of stock was sold by BAFFI ROBERT on Friday, June 22. Ajer Jeffrey Robert sold $129,685 worth of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) or 1,436 shs on Monday, June 11.

Based on the latest 2018Q2 regulatory filing with the SEC, Quantum Capital Management reduced its stake in Biomarin Pharmaceutical Inc (BMRN) by 63.82%. The company’s stock rose 10.80% with the market as Quantum Capital Management sold 80,974 shares. The major pharmaceuticals company reported $4.32M value for the 2018Q2. Now the institutional investor is holding 45,895 shares, compared to the 126,869 from the previous quarter. Quantum Capital Management has risen its stake in and also increased its holding in by shares in the quarter, for a total of shares.

Another two news for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) were briefly posted by: Nasdaq.com on October 30, 2018 with title “Research Report Identifies Deckers Outdoor, Navient, Phillips 66, BioMarin Pharmaceutical, McKesson, and Equity …”. The other Fool.com‘s article was titled “BioMarin Keeps on Pace for Its $2 Billion Goal” and posted on October 31, 2018.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Ratings Coverage

Total analysts of 10 have positions in Biomarin Pharmaceutical (NASDAQ:BMRN) as follows: 9 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 90%. Since May 16, 2018 according to StockzIntelligence Inc Biomarin Pharmaceutical has 18 analyst reports. On Friday, June 15 Wedbush maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with “Buy” rating. On Tuesday, October 23 the firm has “Buy” rating given by Canaccord Genuity. On Thursday, August 9 the rating was maintained by Citigroup with “Buy”. On Monday, July 9 the firm earned “Outperform” rating by Credit Suisse. On Monday, August 6 the firm earned “Outperform” rating by Wedbush. On Friday, May 25 the rating was maintained by Canaccord Genuity with “Buy”. On Tuesday, May 15 the rating was maintained by Wedbush with “Buy”. In Tuesday, May 29 report Wedbush maintained the stock with “Outperform” rating. On Friday, October 26 the rating was maintained by Raymond James with “Outperform”. In Tuesday, July 31 report Canaccord Genuity maintained the stock with “Buy” rating.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.